Loading...

GRANULES Granules India Ltd US FDA Inspections Announcement

Grnl

GRNL

Granules India Ltd

(GRANULES)

2023 Announcement

Show Summary

Summary

AGM Notice Published

Corporate Guarantee

FDA Inspection Update

FDA Inspection Update

Earnings Call Transcript

Management Change

Earnings Call Recording

Investor Presentation

Board Meeting Outcome

Secretarial Compliance

Earnings Call Scheduled

EcoVadis Gold Rating

Office Address Change

Management Change

Acquisition Completed

Change in Management

Subsidiary Dissolved

GST Investigation Update

Management Change

FDA Warning Letter

Acquisition by Granules

CDP Rating Update

Management Change

Q3 Earnings Call

EU GMP Certificate

Earnings Call Audio

Investor Presentation

Q3FY25 Financials

Earnings Call Scheduled

Management Change

FDA Approval Announcement

FDA Inspection Update

FDA Inspection Update

Management Change

Climate Goals Validation

Sustainability Recognition

Earnings Call Transcript

FDA Inspection Success

Investor Meeting Scheduled

Earnings Call Update

Investor Presentation

Q2 FY25 Results

Earnings Call Scheduled

FDA Approval Granted

Management Change

Mobile Cancer Screening

USFDA Inspection Update

FDA Inspection Results

FDA Approval Granted

Clarification Time

ANDA Approval for Trazodone...

Analyst/Investor Meet

Meeting Intimation

Earnings Presentation Q1 FY25

Financial Results Announcement

Newspaper Publication

Investor Meeting

Shareholder Change

Earnings Update

Presentation to Analysts/In...

Financial Results

Board Meeting Outcome

Earnings Conference Call

Tax Liability Communication

ANDA Approval for Colchicin...

Annual Secretarial Complian...

Compliance Certificate Subm...

Compliance Certificate Subm...

FDA Audit Results

Tax Liability Communication

Update on US FDA Inspection

Director Change

Management Change

Clarification on Directors ...

Management Change

Management Change

Meeting Intimation

Postal Ballot Notice Public...

Corporate Guarantee Disclosure

Appointment of Director

Appointment of Additional D...

Change in Senior Management

Earnings Conference Call

Conference Call

Earnings Presentation

Financial Results

Appointment of Directors

Earnings Conference Call

US FDA Inspection

FDA Approval - Sildenafil f...

Investor Conferences

Tax Liability Communication

Earnings Call Transcript

Analyst/Investor Meeting

Conference Call Recording U...

Disclosure of Related Party...

Financial Results Presentation

Financial Results

Preponement of Earnings Con...

Allotment of ESOS

MSCI ESG Rating Update

Analyst/Investor Meeting

Approval from Brazilian Hea...

Accreditation Certificate f...

Earnings Conference Call

Investor Meetings

Investor Meetings

Presentation to Analysts/In...

Financial Statements

Post-Market Surveillance

Publication of Meeting Notice

New Product Launches

Inspection Result

Management Changes

Completed Inspection

Regulatory Compliance

Compliance Report submission

Meeting Schedule

Conference Call Transcript

Related Party Transactions

Submission of Investor Pres...

Financial Statements

External Links:

Data:

Granules Pharmaceuticals, Inc. successfully completes USFDA Post-marketing Adverse Drug Experience (PADE) Inspection with zero observations, indicating a commitment to patient safety and product quality.

AI Assistant

Granules India Ltd

2023

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.